ClinicalTrials.gg
Active, not recruitingNCT05662241INDIGOUpdated Feb 4, 2026

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

A Phase 3 interventional study of Obexelimab and Placebo in IgG4 Related Disease, sponsored by Zenas BioPharma (USA), LLC. Active, not recruiting at 65 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Zenas BioPharma (USA), LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)

Read the detailed description

This study consists of a 1-year randomized control period (RCP), followed by an additional 3-year open label extension (OLE) period.

To enter the Screening Period (Day -28 to Day -1), patients must have active IgG4-RD signs/symptoms (i.e., flare) that require steroid therapy. On Day 1, patients will be randomized in a ratio of 1:1 to receive either obexelimab or placebo administered as subcutaneous (SC) injections. All patients will begin a steroid taper on Day 1 to discontinuation by Week 8.

Patients will be monitored for flares during scheduled in clinic visits and any unscheduled visits. The primary endpoint is time to first IgG4-RD flare that requires initiation of rescue therapy in the opinion of the investigator and the Adjudication Committee (AC).

Following the 52-week RCP, patients will have the opportunity to continue in an OLE period where all patients will receive obexelimab. During the OLE, a subset of patients may be eligible to participate in a sub-study evaluating the immune response to vaccination while receiving obexelimab treatment. Patients who do not wish to enroll into the OLE period will return for an in-clinic safety follow-up visit 8 weeks after the Week 52 visit (i.e., Week 60).

Including screening and follow-up, the maximum duration of participation in this study for an individual patient is 224 weeks (i.e., 28-day screening, 52-week RCP, 156-week OLE, and a 12-week follow-up).

02

Conditions studied

  • IgG4 Related Disease

Keywords

  • IgG4
  • IgG4-RD
03

In context

Immunoglobulin G4-Related Disease

72 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 39 are open to participants now.

This study's enrollment of 194 is above the median of 48 across 52 interventional studies indexed under Immunoglobulin G4-Related Disease.

Browse Immunoglobulin G4-Related Disease studies →

Lead sponsor

Zenas BioPharma (USA), LLC is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, ≥ 18 years of age
  2. Clinical diagnosis of IgG4-RD
  3. Patients must meet the 2019 ACR/EULAR Classification Criteria for IgG4-RD
  4. Patients must have active IgG4-RD signs/symptoms (i.e., flare) that require the initiation of GC therapy or the increase in background long-term GC therapy
  5. Other inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  1. Has disease in only 1 organ system whose primary manifestation is fibrosis
  2. Has received prednisone equivalent given orally at a dose greater than 60 mg/day within the 4 weeks prior to screening or during screening
  3. Has received a non-biologic, disease-modifying anti-rheumatological drug or agent other than GCs within the 2 weeks prior to screening
  4. Has received an treatment or direct medical intervention on another clinical study within 12 weeks or \< 5 half-lives of the investigational treatment, whichever is shorter, prior to screening
  5. Has received or live therapeutic infectious agent within the 2 weeks prior to screening
  6. Active tuberculosis or high risk for tuberculosis; infection in absence of curative treatment; evidence of infection
  7. Use of B cell depleting or targeting agents within 6 months of randomization
  8. Other exclusion criteria apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    ZB012

    Obexelimab administered as an SC injection.

    Drug: Obexelimab

  • Placebo comparator
    Placebo

    Placebo administered as an SC injection.

    Other: Placebo

Interventions

  • Obexelimab is a monoclonal antibody that co-engages CD19 and FcγRIIb to inhibit B cell activity

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Primary outcome measure

    Time to first IgG4-RD flare, defined as the reappearance of previous signs/symptoms or appearance of new signs/symptoms of IgG4-RD that requires initiation of rescue therapy in the opinion of the investigator and the Adjudication Committee (AC), from randomization to Week 52.

    Time frame: Randomization to Week 52

Other outcomes

  1. Vaccine antibody titers

    Vaccine antibody titers at multiple timepoints post-vaccination

    Time frame: During the 3 year OLE period

07

Study locations

65 sites
08

References and documents

Publications

  • Della-Torre E, Baker MC, Zhang W, Perugino CA, Katz G, Tanaka Y, Khosroshahi A, Kleger A, Schleinitz N, Martinez-Valle F, Schulze-Koops H, Nakayamada S, Rebours V, Okazaki K, Dong L, Carruthers M, Chen LYC, Frulloni L, Meysami A, Takahashi H, Kawano M, Liu Y, Saeki T, Ebbo M, Alexander T, Gonzalez Garcia A, Karadag O, Maslinska M, Quinn SM, Poma A, Wells A, Greene TJ, Stone JH, Culver EL; INDIGO Trial Investigators. Obexelimab for the Treatment of IgG4-Related Disease. N Engl J Med. 2026 Jun 2. doi: 10.1056/NEJMoa2601337. Online ahead of print. PubMed 42233621 ↗
  • Culver EL, Baker MC, Della-Torre E, Zhang W, Perugino CA, Wells A, Mamuye A, Quinn SM, Poma A, Greene TJ, Stone JH. Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial. Rheumatol Ther. 2026 Jun;13(3):867-880. doi: 10.1007/s40744-026-00835-4. Epub 2026 Mar 16. PubMed 41840328 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Nov 2025, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2022
First posted
Dec 22, 2022
StartActual
Jan 9, 2023
Primary completionActual
Nov 13, 2025
CompletionEst.
Feb 15, 2029
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05662241
Lead sponsor
Zenas BioPharma (USA), LLC
Responsible party
Sponsor
First posted
Dec 22, 2022
Start date
Jan 9, 2023
Primary completion
Nov 13, 2025
Completion
Feb 15, 2029 (estimated)
Last update
Feb 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obexelimab

Start the discussion